

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application.

The claims have been amended to remove the improper multiple dependencies.

Attached hereto is a marked-up version showing the changes made to the application by this Amendment.

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 

Andrew D. Meikle, #32,868

ADM/ka  
3893-0139P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachment: VERSION WITH MARKINGS TO SHOW CHANGES MADE

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE CLAIMS:**

The claims have been amended as follows:

3. (Amended) A compound according to [any one of the preceding claims] claim 1 or 2 wherein R<sub>1</sub> represents one or more, same or different substituents selected from the group consisting of fluoro, chloro, bromo, hydroxy, methyl, or methoxy.

4. (Amended) A compound according to [any one of the preceding claims] claim 1, wherein R<sub>1</sub> is methyl and R<sub>2</sub> is Cl.

6. (Amended) A pharmaceutical composition containing as an active ingredient a compound according to [any one of claims 1 to 5] claim 1 together with a pharmaceutically acceptable carrier and optionally together with a second active ingredient optionally selected from the group consisting of glucocorticoids, vitamins D's, anti-histamines, platelet activating factor (PAF) antagonists, anticholinergic agents, methyl xanthines,  $\beta$ -adrenergic agents, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum cholesterol-reducing agents, retinoids, zinc salts, and salicylazosulfapyridin (Salazopyrin).

7. (Amended) Use of a compound according to [any one of claim 1 to 5] claim 1 for the preparation of a medicament for the treatment and/or prophylaxis of asthma, allergy, arthritis, including rheumatoid arthritis and spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease (Crohn's disease), proliferative and inflammatory skin disorders, such as psoriasis, atopic dermatitis, uveitis, septic shock, AIDS, osteoporosis and acne.

8. (Amended) A method for the treatment and/or prophylaxis of asthma, allergy, arthritis, including rheumatoid arthritis and spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease (Crohn's disease), proliferative and inflammatory skin disorders, such as psoriasis, atopic dermatitis, uveitis, septic shock, AIDS, osteoporosis and acne, characterised in administering to a patient suffering from at least one of said diseases an effective amount of one or more compounds according to [any one of claims 1 to 5] claim 1 as an active ingredient alone, or if necessary together with a pharmaceutically acceptable carrier, and, optionally, a second active ingredient optionally selected from the group consisting of glucocorticoids, vitamin D's, anti-histamines, platelet activating factor (PAF) antagonists, anticholinergic agents, methyl xanthines,  $\beta$ -adrenergic agents, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum

cholesterol-reducing agents, retinoids, zinc salts, and salicylazosulfapyridin (Salazopyrin).

9. (Amended) A method of treatment according to [the preceding claim] claim 1 comprising administering to a mammal in need of systemic treatment a suitable dose of a compound of formula I of from 0.1 to 200 mg/kg bodyweight, preferably a dose of from 0.2 to 50 mg/kg of mammal bodyweight one or more times daily.

2023-09-08 09:00:00